The Role of MicroRNAs in the Diagnosis and Treatment of Oral Premalignant Disorders

Overview

Journal Odontology

Specialty Dentistry

Date 2024 Apr 15

PMID 38619695

Authors

J H Shazia Fathima

Selvaraj Jayaraman

Ramya Sekar

Nazmul Huda Syed

Affiliations

Soon will be listed here.

Abstract

Oral premalignant disorders (OPMDs) are a group of potentially malignant conditions that pose a significant health burden globally. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as crucial regulators of gene expression and have been implicated in various biological processes, including carcinogenesis. This review synthesizes existing knowledge to provide a comprehensive understanding of the molecular mechanisms underlying OPMDs and to highlight the potential of miRNAs as promising biomarkers and therapeutic targets. Additionally, this review seeks to explore the potential of miRNA-based diagnostic biomarkers for early detection of OPMDs in the current literature on miRNAs in OPMDs, examining their involvement in disease pathogenesis, diagnostic potential, and therapeutic implications. Dysregulated miRNAs can target genes involved in critical cellular processes, such as cell cycle regulation, apoptosis, and DNA repair, leading to disease progression. Notably, miR-21, miR-31, miR-135b, and miR-486-5p have shown promise as potential biomarkers for early detection of oral premalignant lesions. Furthermore, the paper discusses the therapeutic implications of miRNAs in OPMDs. Preclinical studies have demonstrated the efficacy of miRNA-targeted therapies, such as miRNA mimics and inhibitors, in suppressing the growth of oral premalignant lesions. Early-phase clinical trials have shown promising results, indicating the potential for personalized treatment approaches. The findings underscore the importance of understanding the molecular mechanisms underlying these disorders and provide insights for the development of improved diagnostic and therapeutic strategies. However, they pose certain limitations given their intrinsic variability in expression profiles, the need for optimized isolation and detection methods, and potential hurdles in transitioning from preclinical success to clinical applications. Thus, future clinical studies are warranted to fully exploit the potential of miRNAs in the management of OPMDs.

Citing Articles

Ceramide Ehux-C22 Targets the miR-199a-3p/mTOR Signaling Pathway to Regulate Melanosomal Autophagy in Mouse B16 Cells.

Wan J, Zhang S, Li G, Huang S, Li J, Zhang Z Int J Mol Sci. 2024; 25(15).

PMID: 39125630 PMC: 11312279. DOI: 10.3390/ijms25158061.

References

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View

Sankaranarayanan R, Ramadas K, Qiao Y . Managing the changing burden of cancer in Asia. BMC Med. 2014; 12:3. PMC: 4029284. DOI: 10.1186/1741-7015-12-3. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Peng Y, Croce C . The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2017; 1:15004. PMC: 5661652. DOI: 10.1038/sigtrans.2015.4. View

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

Rauhut R, Lendeckel W, Tuschl T . Identification of novel genes coding for small expressed RNAs. Science. 2001; 294(5543):853-8. DOI: 10.1126/science.1064921. View

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

10.

Gorenchtein M, Poh C, Saini R, Garnis C . MicroRNAs in an oral cancer context - from basic biology to clinical utility. J Dent Res. 2011; 91(5):440-6. DOI: 10.1177/0022034511431261. View

11.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

12.

Manikandan M, Deva Magendhra Rao A, Arunkumar G, Manickavasagam M, Rajkumar K, Rajaraman R . Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism. Mol Cancer. 2016; 15:28. PMC: 4823852. DOI: 10.1186/s12943-016-0512-8. View

13.

Bouquot J, GORLIN R . Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986; 61(4):373-81. DOI: 10.1016/0030-4220(86)90422-6. View

14.

Warnakulasuriya S, Johnson N, van der Waal I . Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007; 36(10):575-80. DOI: 10.1111/j.1600-0714.2007.00582.x. View

15.

Warnakulasuriya S, Kujan O, Aguirre-Urizar J, Bagan J, Gonzalez-Moles M, Kerr A . Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2020; 27(8):1862-1880. DOI: 10.1111/odi.13704. View

16.

Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z . Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018; 18(1):911. PMC: 6151070. DOI: 10.1186/s12885-018-4806-7. View

17.

Liu C, Tsai M, Hung P, Kao S, Liu T, Wu K . miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010; 70(4):1635-44. DOI: 10.1158/0008-5472.CAN-09-2291. View

18.

Liu W, Zhao X, Zhang Y, Fang G, Xue Y . MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res. 2017; 46(3):975-983. PMC: 5972241. DOI: 10.1177/0300060517734114. View

19.

Wang L, Chen W, Zha J, Yan Y, Wei Y, Chen X . miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5. Oncol Rep. 2019; 42(3):973-990. PMC: 6667884. DOI: 10.3892/or.2019.7230. View

20.

Chen H, Liu X, Jin Z, Gou C, Liang M, Cui L . A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma. Am J Cancer Res. 2018; 8(8):1403-1413. PMC: 6129488. View